Valeant has many excellent assets that can be sold if needed to pay down the debt. One of the best of these is Wellbutrin - a unique MAOI anti-depressant with a non-anhedonic side effect profile (no reduction in libido etc), which can also be used to treat ADHD. Wellbutrin is one of Valeant's best assets because it is still going strong despite generic competition. Here is the drugs performance in 2015. Growth in a drug that has been around since the 80's!Quarter 1 Quarter 2 Quarter 3 Quarter 4$68,000,000 $67,000,000 $92,000,000 $93,000,000 Why is Wellbutrin so resilient? Wellbutrin has a high terminal value because the brand name is simply superior to the generic. To date no generic version of the drug has been able to replicate the efficacy of the original. Doctors and patients know this, so they specifically ask for brand name Wellbutrin in prescriptions. Conclusion. If you are making a spreadsheet model for Valeant, make sure to keep the tail sales of Wellbutrin constant for the next 10 years. I predict the drug should see sales of about $300 million per year far into the future.